May C Chen, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
16 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G83884 · Current
Licensed to practise in California · since 1997 · expires 2027-06-30 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$114,018
Medicare paid this office $114,018 for 607 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 282 | $44,027 | $87 |
| Short return visit (20+ min) | 337 | $26,699 | $53 |
| New patient visit (60+ min) | 76 | $11,515 | $152 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 379 | $9,278 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $7,673 | $105 |
See all 9 services
| Return visit (30+ min) | 282 | $44,027 | $87 |
| Short return visit (20+ min) | 337 | $26,699 | $53 |
| New patient visit (60+ min) | 76 | $11,515 | $152 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 379 | $9,278 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $7,673 | $105 |
| New patient visit (45+ min) | 37 | $5,639 | $152 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,553 | $154 |
| Long return visit (40+ min) | 21 | $2,990 | $136 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $919 | $44 |
Who their Medicare patients are
607 Original Medicare patients in 2024. Average age 75 · Under 65 4% · 85 and older 13% · Women 75% · Also on Medicaid 13% · Health risk score 1.65. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: Cancer 72% · High blood pressure 70% · Diabetes 32% · Coronary heart disease 25% · Chronic kidney disease 21% · Heart failure 18% · Atrial fibrillation 18% · Depression 17% · COPD 10% · Stroke 9% · Dementia 7%.
The office billed $342,774, Medicare allowed $152,511 and paid $114,018; for 1,908 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 607 | 1,908 | 75 | 1.65 | $342,774 | $114,018 |
| 2023 | 576 | 1,253 | 76 | 1.61 | $273,676 | $99,695 |
| 2022 | 595 | 1,336 | 76 | 1.63 | $346,859 | $99,702 |
| 2021 | 597 | 1,464 | 76 | 1.67 | $436,269 | $113,035 |
| 2020 | 531 | 1,280 | 76 | 1.87 | $291,270 | $79,562 |
| 2019 | 579 | 1,549 | 75 | 1.62 | $203,295 | $93,616 |
| 2018 | 537 | 1,372 | 75 | 1.72 | $147,877 | $74,780 |
| 2017 | 538 | 1,405 | 75 | 1.67 | $199,463 | $77,172 |
| 2016 | 488 | 1,554 | 75 | 1.79 | $221,306 | $81,837 |
| 2015 | 467 | 61,944 | 76 | 1.65 | $3,496,160 | $726,563 |
| 2014 | 566 | 184,785 | 76 | 1.86 | $8,464,495 | $1,763,636 |
| 2013 | 695 | 81,186 | 76 | 1.83 | $5,939,201 | $1,446,836 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 243 | $34,932 | $81 |
| Short return visit (20+ min) | 321 | $24,538 | $53 |
| New patient visit (60+ min) | 82 | $12,492 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $11,255 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $5,157 | $156 |
| New patient visit (45+ min) | 29 | $3,475 | $120 |
| Long return visit (40+ min) | 28 | $3,427 | $111 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 19 | $1,633 | $44 |
| Return visit (30+ min) | 11 | $816 | $74 |
2022: 10 services
| Short return visit (20+ min) | 383 | $32,979 | $52 |
| Return visit (30+ min) | 172 | $22,572 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $12,886 | $93 |
| New patient visit (60+ min) | 74 | $12,253 | $166 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $6,061 | $178 |
| Long return visit (40+ min) | 36 | $4,932 | $123 |
| New patient visit (45+ min) | 27 | $3,005 | $111 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 35 | $2,492 | $35 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $898 | $82 |
| Telephone medical discussion with physician, 11-20 minutes | 29 | $792 | $26 |
2021: 10 services
| Short return visit (20+ min) | 379 | $34,308 | $53 |
| Return visit (30+ min) | 166 | $23,359 | $87 |
| New patient visit (60+ min) | 92 | $15,392 | $167 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $13,937 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $7,217 | $185 |
| Long return visit (40+ min) | 44 | $6,296 | $126 |
| New patient visit (45+ min) | 29 | $3,697 | $127 |
| Telephone medical discussion with physician, 11-20 minutes | 69 | $3,638 | $51 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 39 | $3,008 | $35 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,304 | $87 |
2020: 8 services
| Short return visit (20+ min) | 400 | $35,272 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $15,135 | $97 |
| New patient visit (60+ min) | 64 | $9,393 | $147 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $7,144 | $188 |
| Return visit (30+ min) | 45 | $4,103 | $75 |
| Long return visit (40+ min) | 41 | $3,861 | $94 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 31 | $2,029 | $36 |
| New patient visit (45+ min) | 15 | $1,564 | $104 |
2019: 8 services
| Short return visit (20+ min) | 434 | $42,304 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $18,489 | $94 |
| New patient visit (60+ min) | 86 | $12,557 | $146 |
| Long return visit (40+ min) | 55 | $5,608 | $100 |
| New patient visit (45+ min) | 35 | $3,965 | $113 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,854 | $184 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 34 | $3,090 | $36 |
| Return visit (30+ min) | 34 | $2,972 | $69 |
2018: 7 services
| Short return visit (20+ min) | 418 | $41,764 | $41 |
| New patient visit (60+ min) | 74 | $10,414 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $9,081 | $94 |
| New patient visit (45+ min) | 50 | $5,124 | $102 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 35 | $2,693 | $35 |
| Long return visit (40+ min) | 25 | $2,282 | $91 |
| Return visit (30+ min) | 21 | $1,413 | $64 |
2017: 7 services
| Short return visit (20+ min) | 411 | $41,514 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $11,900 | $93 |
| New patient visit (60+ min) | 73 | $10,062 | $138 |
| New patient visit (45+ min) | 45 | $4,736 | $105 |
| Long return visit (40+ min) | 36 | $3,587 | $97 |
| Return visit (30+ min) | 32 | $2,274 | $69 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 30 | $1,886 | $35 |
2016: 6 services
| Short return visit (20+ min) | 386 | $48,259 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $10,833 | $93 |
| New patient visit (60+ min) | 59 | $8,444 | $143 |
| Long return visit (40+ min) | 63 | $5,856 | $90 |
| Return visit (30+ min) | 54 | $4,540 | $65 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 31 | $2,058 | $35 |
2015: 22 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $83,041 | None |
| Short return visit (20+ min) | 328 | $53,626 | $62 |
| Short return visit (20+ min) | 298 | $26,548 | $45 |
| Administration of chemotherapy into vein, 1 hour or less | 29 | $21,363 | $138 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $12,429 | $92 |
| Injection, palonosetron hcl, 25 mcg | 16 | $10,902 | None |
| Injection of drug or substance under skin or into muscle | 43 | $8,370 | $25 |
| New patient visit (60+ min) | 29 | $5,383 | $186 |
| New patient visit (60+ min) | 35 | $5,091 | $145 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 19 | $4,522 | $30 |
| Injection of additional new drug or substance into vein | 28 | $4,402 | $22 |
| Administration of additional new drug or substance into vein, 1 hour or less | 12 | $4,129 | $64 |
| Administration of chemotherapy into vein, each additional hour | 15 | $3,127 | $28 |
| Infusion into a vein for hydration, 31-60 minutes | 11 | $2,753 | $57 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 38 | $2,721 | $34 |
| Long return visit (40+ min) | 20 | $1,971 | $99 |
| Infusion into a vein for hydration, each additional hour | 14 | $1,956 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 12 | $1,914 | $68 |
| Short return visit | 17 | $1,178 | $41 |
| Return visit (30+ min) | 13 | $1,113 | $70 |
| Irrigation of implanted venous access drug delivery device | 17 | $601 | $22 |
| Injection, dexamethasone sodium phosphate, 1 mg | 16 | $81 | None |
2014: 35 services
| Injection, rituximab, 100 mg | 12 | $210,659 | None |
| Injection, pegfilgrastim, 6 mg | 16 | $179,493 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 27 | $155,379 | None |
| Short return visit (20+ min) | 479 | $109,113 | $64 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 24 | $79,904 | None |
| Administration of chemotherapy into vein, 1 hour or less | 47 | $42,044 | $137 |
| Injection, palonosetron hcl, 25 mcg | 33 | $27,180 | None |
| Injection of drug or substance under skin or into muscle | 78 | $19,970 | $25 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $14,197 | $92 |
| Injection, zoledronic acid, 1 mg | 18 | $12,127 | None |
| Injection, fosaprepitant, 1 mg | 15 | $10,937 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $10,322 | $63 |
| New patient visit (60+ min) | 57 | $10,247 | $180 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 43 | $9,342 | $30 |
| Injection of additional new drug or substance into vein | 46 | $7,949 | $22 |
| Return visit (30+ min) | 54 | $7,298 | $100 |
| Administration of chemotherapy into vein, each additional hour | 27 | $7,192 | $28 |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $4,521 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,497 | $180 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 49 | $3,991 | $35 |
| Long return visit (40+ min) | 28 | $3,824 | $127 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $3,516 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 18 | $3,365 | $69 |
| Infusion into a vein for hydration, each additional hour | 23 | $2,926 | $15 |
| Short return visit | 37 | $2,324 | $42 |
| Administration of influenza virus vaccine | 43 | $1,231 | $29 |
| Irrigation of implanted venous access drug delivery device | 18 | $1,019 | $23 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 20 | $880 | $20 |
| Injection, carboplatin, 50 mg | 12 | $675 | None |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 39 | $588 | $15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 33 | $246 | None |
| Injection, ranitidine hydrochloride, 25 mg | 20 | $93 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 25 | $41 | None |
| Injection, lorazepam, 2 mg | 11 | $28 | None |
| Injection, potassium chloride, per 2 meq | 17 | $25 | None |
2013: 41 services
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 39 | $152,224 | None |
| Short return visit (20+ min) | 596 | $134,529 | $63 |
| Injection, pegfilgrastim, 6 mg | 13 | $109,750 | None |
| Injection, filgrastim (g-csf), 480 mcg | 15 | $62,188 | None |
| Administration of chemotherapy into vein, 1 hour or less | 56 | $50,279 | $146 |
| Fecal microbiota, live - jslm, 1 ml | 14 | $44,408 | None |
| Injection, palonosetron hcl, 25 mcg | 41 | $31,075 | None |
| Zoldedronic acid 1mg | 18 | $23,541 | $138 |
| Injection of drug or substance under skin or into muscle | 92 | $23,538 | $25 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $17,914 | $90 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $13,855 | $73 |
| New patient visit (60+ min) | 76 | $13,603 | $179 |
| Administration of prolonged chemotherapy into vein | 12 | $11,054 | $147 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 50 | $10,510 | $32 |
| Return visit (30+ min) | 72 | $8,676 | $94 |
| Injection of additional new drug or substance into vein | 52 | $8,405 | $23 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 84 | $8,031 | $33 |
| Long return visit (40+ min) | 56 | $7,244 | $127 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 27 | $6,154 | $77 |
| Administration of chemotherapy into vein, each additional hour | 27 | $5,784 | $31 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,347 | $172 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 15 | $5,267 | None |
| Infusion into a vein for hydration, 31-60 minutes | 20 | $4,275 | $57 |
| Infusion into a vein for hydration, each additional hour | 32 | $3,569 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 27 | $2,206 | $18 |
| Biopsy of bone marrow | 13 | $2,035 | $157 |
| Administration of influenza virus vaccine | 56 | $1,527 | $27 |
| Short return visit | 32 | $1,466 | $42 |
| Injection, paclitaxel, 30 mg | 11 | $1,420 | None |
| Irrigation of implanted venous access drug delivery device | 16 | $1,327 | $25 |
| Injection, fluorouracil, 500 mg | 13 | $1,046 | None |
| Injection, carboplatin, 50 mg | 15 | $1,004 | None |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 54 | $783 | $14 |
| Injection, granisetron hydrochloride, 100 mcg | 16 | $312 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 39 | $288 | None |
| Injection, ranitidine hydrochloride, 25 mg | 29 | $255 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 13 | $151 | $12 |
| Injection, diphenhydramine hcl, up to 50 mg | 30 | $94 | None |
| 5% dextrose/normal saline (500 ml = 1 unit) | 23 | $86 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 13 | $59 | None |
| Injection, potassium chloride, per 2 meq | 23 | $11 | None |
Medicaid work
$221 in 2023
Medicaid paid $221 for 15 billed services this clinician did in 2023, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 15 | $221 |
| 2023 | 15 | 1 | 14 | $221 |
| 2022 | 31 | 1 | 15 | $391 |
| 2021 | 66 | 1 | 14 | $1,365 |
| 2020 | 70 | 1 | 16 | $1,258 |
| 2019 | 103 | 1 | 17 | $1,573 |
| 2018 | 111 | 1 | 16 | $1,746 |
See the largest Medicaid services in earlier years
2022
| Short return visit (20+ min) | 31 | $391 |
2021
| Short return visit (20+ min) | 66 | $1,365 |
2020
| Short return visit (20+ min) | 70 | $1,258 |
2019
| Short return visit (20+ min) | 103 | $1,573 |
2018
| Short return visit (20+ min) | 111 | $1,746 |
Drugs they prescribed that Part D paid
$775,271
Pharmacies billed $775,271 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (11 of 642) in 2024. At or below the middle of the specialty; the typical medical oncology clinician is at 6%.
544 generic and fewer than 11 brand-name prescriptions · $775,271 in drug cost · 17 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 11 | $163,878 | $14,898 |
| Verzenio | 11 | $146,098 | $13,282 |
| Eliquis | 20 | $17,970 | $898 |
| Exemestane | 12 | $3,154 | $263 |
| Dexamethasone | 33 | $662 | $20 |
See all 15 drugs
| Tagrisso | 11 | $163,878 | $14,898 |
| Verzenio | 11 | $146,098 | $13,282 |
| Eliquis | 20 | $17,970 | $898 |
| Exemestane | 12 | $3,154 | $263 |
| Dexamethasone | 33 | $662 | $20 |
| Prochlorperazine Maleate | 66 | $642 | $10 |
| Anastrozole | 57 | $609 | $11 |
| Letrozole | 18 | $458 | $25 |
| Ondansetron | 63 | $389 | $6 |
| Potassium Chloride | 16 | $365 | $23 |
| Gabapentin | 18 | $151 | $8 |
| Loperamide | 12 | $110 | $9 |
| Lorazepam | 24 | $64 | $3 |
| Furosemide | 16 | $52 | $3 |
| Prednisone | 11 | $47 | $4 |
Year by year
| 2024 | 642 | 161 | 2% (11) | None | $775,271 |
| 2023 | 608 | 162 | 3% (17) | None | $662,614 |
| 2022 | 494 | 143 | 3% (14) | 12% | $444,495 |
| 2021 | 636 | 157 | 5% (32) | 18% | $782,876 |
| 2020 | 623 | 150 | 4% (23) | 27% | $969,269 |
| 2019 | 954 | 207 | 3% (29) | 16% | $1,056,812 |
| 2018 | 1,307 | 234 | 5% (68) | 17% | $901,254 |
| 2017 | 1,555 | 207 | 7% (106) | 18% | $762,650 |
| 2016 | 1,460 | 201 | 8% (115) | 19% | $802,776 |
| 2015 | 1,374 | 194 | 7% (89) | None | $546,288 |
| 2014 | 1,596 | 202 | 9% (140) | None | $523,166 |
| 2013 | 1,763 | 217 | 9% (160) | None | $679,877 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Eliquis | 25 | $24,562 | $982 |
| Exemestane | 14 | $2,910 | $208 |
| Anastrozole | 54 | $1,359 | $25 |
| Letrozole | 30 | $838 | $28 |
| Prochlorperazine Maleate | 65 | $646 | $10 |
| Dexamethasone | 18 | $554 | $31 |
| Ondansetron | 69 | $415 | $6 |
| Alendronate | 14 | $204 | $15 |
| Famotidine | 12 | $196 | $16 |
| Loperamide | 13 | $180 | $14 |
| Amoxicillin-Clavulanate Potass | 11 | $142 | $13 |
| Lorazepam | 23 | $133 | $6 |
| Prednisone | 16 | $130 | $8 |
2022: 11 drugs
| Revlimid | 13 | $233,118 | $17,932 |
| Exemestane | 16 | $5,086 | $318 |
| Letrozole | 37 | $1,056 | $29 |
| Anastrozole | 42 | $891 | $21 |
| Dexamethasone | 24 | $740 | $31 |
| Ondansetron | 34 | $635 | $19 |
| Acyclovir | 19 | $429 | $23 |
| Prochlorperazine Maleate | 28 | $303 | $11 |
| Sulfamethoxazole-Trimethoprim | 25 | $107 | $4 |
| Prednisone | 16 | $65 | $4 |
| Lorazepam | 13 | $39 | $3 |
2021: 18 drugs
| Revlimid | 13 | $190,884 | $14,683 |
| Imbruvica | 13 | $73,096 | $5,623 |
| Xarelto | 11 | $5,467 | $497 |
| Exemestane | 17 | $4,770 | $281 |
| Letrozole | 33 | $1,272 | $39 |
| Anastrozole | 46 | $1,158 | $25 |
| Prochlorperazine Maleate | 56 | $822 | $15 |
| Ondansetron | 42 | $782 | $19 |
| Dexamethasone | 23 | $765 | $33 |
| Hydroxyurea | 11 | $414 | $38 |
| Acyclovir | 20 | $407 | $20 |
| Sulfamethoxazole-Trimethoprim | 35 | $228 | $7 |
| Gabapentin | 13 | $225 | $17 |
| Loperamide | 18 | $172 | $10 |
| Hydrocodone-Acetaminophen | 15 | $139 | $9 |
| Warfarin | 11 | $110 | $10 |
| Lorazepam | 18 | $79 | $4 |
| Prednisone | 14 | $47 | $3 |
2020: 19 drugs
| Ibrance | 18 | $229,464 | $12,748 |
| Imatinib Mesylate | 15 | $13,813 | $921 |
| Xarelto | 20 | $13,655 | $683 |
| Enoxaparin | 14 | $10,526 | $752 |
| Exemestane | 29 | $8,548 | $295 |
| Eliquis | 11 | $7,244 | $659 |
| Megestrol Acetate | 17 | $947 | $56 |
| Letrozole | 26 | $855 | $33 |
| Pregabalin | 14 | $732 | $52 |
| Ondansetron | 48 | $593 | $12 |
| Prochlorperazine Maleate | 44 | $530 | $12 |
| Dexamethasone | 17 | $504 | $30 |
| Venlafaxine Hcl Er | 16 | $383 | $24 |
| Anastrozole | 28 | $360 | $13 |
| Acyclovir | 11 | $349 | $32 |
| Levothyroxine | 12 | $327 | $27 |
| Warfarin | 13 | $244 | $19 |
| Omeprazole | 11 | $202 | $18 |
| Lorazepam | 20 | $55 | $3 |
2019: 23 drugs
| Pomalyst | 15 | $277,781 | $18,519 |
| Exemestane | 44 | $14,992 | $341 |
| Entecavir | 12 | $9,923 | $827 |
| Eliquis | 19 | $8,862 | $466 |
| Xarelto | 13 | $6,424 | $494 |
| Enoxaparin | 14 | $2,945 | $210 |
| Anastrozole | 116 | $2,448 | $21 |
| Letrozole | 65 | $1,678 | $26 |
| Ondansetron | 60 | $779 | $13 |
| Levothyroxine | 29 | $718 | $25 |
| Hydroxyurea | 13 | $715 | $55 |
| Dexamethasone | 19 | $579 | $30 |
| Prochlorperazine Maleate | 54 | $470 | $9 |
| Venlafaxine Hcl Er | 26 | $449 | $17 |
| Acyclovir | 11 | $446 | $41 |
| Warfarin | 25 | $426 | $17 |
| Potassium Chloride | 18 | $403 | $22 |
| Gabapentin | 14 | $396 | $28 |
| Amoxicillin-Clavulanate Potass | 12 | $315 | $26 |
| Hydrocodone-Acetaminophen | 16 | $270 | $17 |
| Sulfamethoxazole-Trimethoprim | 11 | $152 | $14 |
| Prednisone | 18 | $134 | $7 |
| Lorazepam | 22 | $108 | $5 |
2018: 32 drugs
| Promacta | 18 | $147,241 | $8,180 |
| Imatinib Mesylate | 20 | $58,443 | $2,922 |
| Creon | 22 | $45,158 | $2,053 |
| Exemestane | 74 | $33,510 | $453 |
| Xarelto | 30 | $16,023 | $534 |
| Eliquis | 11 | $5,633 | $512 |
| Anastrozole | 130 | $2,388 | $18 |
| Letrozole | 60 | $1,360 | $23 |
| Hydroxyurea | 27 | $863 | $32 |
| Bumetanide | 18 | $826 | $46 |
| Gabapentin | 23 | $799 | $35 |
| Dexamethasone | 27 | $750 | $28 |
| Megestrol Acetate | 18 | $724 | $40 |
| Venlafaxine Hcl Er | 29 | $585 | $20 |
| Levothyroxine | 28 | $566 | $20 |
| Ondansetron | 75 | $549 | $7 |
| Oxycodone-Acetaminophen | 13 | $502 | $39 |
| Hydrocodone-Acetaminophen | 27 | $485 | $18 |
| Acyclovir | 16 | $471 | $29 |
| Warfarin | 30 | $446 | $15 |
| Synthroid | 11 | $425 | $39 |
| Potassium Chloride | 21 | $377 | $18 |
| Prochlorperazine Maleate | 46 | $303 | $7 |
| Tamsulosin | 20 | $221 | $11 |
| Omeprazole | 24 | $199 | $8 |
| Zolpidem | 31 | $193 | $6 |
| Nystatin | 11 | $160 | $15 |
| Dicyclomine | 11 | $136 | $12 |
| Escitalopram | 14 | $125 | $9 |
| Lorazepam | 32 | $113 | $4 |
| Prednisone | 16 | $106 | $7 |
| Levofloxacin | 16 | $106 | $7 |
2017: 44 drugs
| Creon | 63 | $83,140 | $1,320 |
| Tarceva | 12 | $82,551 | $6,879 |
| Promacta | 13 | $72,005 | $5,539 |
| Exemestane | 91 | $41,048 | $451 |
| Fondaparinux | 13 | $19,482 | $1,499 |
| Xarelto | 31 | $13,631 | $440 |
| Entecavir | 12 | $10,102 | $842 |
| Eliquis | 18 | $8,581 | $477 |
| Enoxaparin | 12 | $3,898 | $325 |
| Anastrozole | 110 | $2,017 | $18 |
| Hydroxyzine | 14 | $1,403 | $100 |
| Letrozole | 44 | $1,309 | $30 |
| Diphenoxylate-Atropine | 12 | $902 | $75 |
| Megestrol Acetate | 23 | $887 | $39 |
| Hydroxyurea | 19 | $842 | $44 |
| Oxycodone | 25 | $765 | $31 |
| Acyclovir | 27 | $667 | $25 |
| Venlafaxine Hcl Er | 50 | $609 | $12 |
| Gabapentin | 32 | $574 | $18 |
| Ondansetron | 64 | $572 | $9 |
| Warfarin | 43 | $559 | $13 |
| Zolpidem | 36 | $464 | $13 |
| Levothyroxine | 25 | $405 | $16 |
| Omeprazole | 31 | $400 | $13 |
| Potassium Chloride | 15 | $392 | $26 |
| Hydrocodone-Acetaminophen | 32 | $346 | $11 |
| Dexamethasone | 25 | $345 | $14 |
| Duloxetine | 11 | $325 | $30 |
| Pantoprazole | 21 | $320 | $15 |
| Prochlorperazine Maleate | 49 | $307 | $6 |
| Nystatin | 11 | $275 | $25 |
| Lorazepam | 56 | $247 | $4 |
| Paroxetine | 22 | $212 | $10 |
| Prednisone | 26 | $211 | $8 |
| Escitalopram | 22 | $178 | $8 |
| Sulfamethoxazole-Trimethoprim | 14 | $177 | $13 |
| Oxycodone-Acetaminophen | 14 | $136 | $10 |
| Levofloxacin | 15 | $120 | $8 |
| Metoclopramide | 14 | $102 | $7 |
| Pravastatin | 11 | $101 | $9 |
| Diazepam | 11 | $79 | $7 |
| Amlodipine Besylate | 13 | $78 | $6 |
| Atorvastatin | 13 | $72 | $6 |
| Furosemide | 17 | $57 | $3 |
2016: 38 drugs
| Tarceva | 16 | $91,421 | $5,714 |
| Exemestane | 85 | $28,610 | $337 |
| Fondaparinux | 13 | $27,736 | $2,134 |
| Creon | 18 | $20,667 | $1,148 |
| Entecavir | 13 | $13,857 | $1,066 |
| Oxycontin | 15 | $9,721 | $648 |
| Enoxaparin | 26 | $8,328 | $320 |
| Anastrozole | 102 | $2,257 | $22 |
| Oxycodone | 28 | $1,619 | $58 |
| Oxycodone-Acetaminophen | 18 | $1,223 | $68 |
| Potassium Chloride | 22 | $1,119 | $51 |
| Warfarin | 71 | $833 | $12 |
| Ondansetron | 64 | $774 | $12 |
| Zolpidem | 35 | $589 | $17 |
| Gabapentin | 22 | $542 | $25 |
| Megestrol Acetate | 12 | $530 | $44 |
| Tamoxifen Citrate | 19 | $528 | $28 |
| Nystatin | 18 | $516 | $29 |
| Lorazepam | 74 | $455 | $6 |
| Letrozole | 35 | $440 | $13 |
| Levothyroxine | 25 | $437 | $17 |
| Hydrocodone-Acetaminophen | 20 | $375 | $19 |
| Venlafaxine Hcl Er | 31 | $337 | $11 |
| Prochlorperazine Maleate | 45 | $329 | $7 |
| Hydroxyzine | 12 | $310 | $26 |
| Pantoprazole | 22 | $243 | $11 |
| Dexamethasone | 18 | $229 | $13 |
| Hydromorphone | 12 | $208 | $17 |
| Sulfamethoxazole-Trimethoprim | 14 | $204 | $15 |
| Furosemide | 39 | $201 | $5 |
| Escitalopram | 25 | $192 | $8 |
| Omeprazole | 14 | $186 | $13 |
| Paroxetine | 25 | $179 | $7 |
| Levofloxacin | 12 | $130 | $11 |
| Prednisone | 25 | $121 | $5 |
| Alendronate | 11 | $91 | $8 |
| Amlodipine Besylate | 15 | $90 | $6 |
| Metoprolol | 16 | $60 | $4 |
2015: 42 drugs
| Revlimid | 13 | $131,879 | $10,145 |
| Tarceva | 13 | $79,136 | $6,087 |
| Exemestane | 89 | $33,847 | $380 |
| Fondaparinux | 13 | $29,366 | $2,259 |
| Enoxaparin | 12 | $10,533 | $878 |
| Creon | 17 | $6,891 | $405 |
| Anastrozole | 129 | $2,057 | $16 |
| Oxycodone-Acetaminophen | 17 | $1,109 | $65 |
| Hydroxyurea | 27 | $1,017 | $38 |
| Hydroxyzine | 17 | $776 | $46 |
| Tamoxifen Citrate | 18 | $723 | $40 |
| Levothyroxine | 39 | $673 | $17 |
| Acyclovir | 21 | $670 | $32 |
| Potassium Chloride | 20 | $627 | $31 |
| Venlafaxine Hcl Er | 36 | $618 | $17 |
| Nystatin | 20 | $613 | $31 |
| Ondansetron | 50 | $539 | $11 |
| Letrozole | 20 | $424 | $21 |
| Gabapentin | 28 | $418 | $15 |
| Acetaminophen-Codeine | 13 | $333 | $26 |
| Lorazepam | 80 | $319 | $4 |
| Hydrocodone-Acetaminophen | 11 | $241 | $22 |
| Zolpidem | 20 | $234 | $12 |
| Hydromorphone | 12 | $217 | $18 |
| Prednisone | 21 | $208 | $10 |
| Prochlorperazine Maleate | 34 | $201 | $6 |
| Levofloxacin | 16 | $198 | $12 |
| Pantoprazole | 25 | $195 | $8 |
| Dexamethasone | 12 | $193 | $16 |
| Alendronate | 22 | $184 | $8 |
| Escitalopram | 35 | $176 | $5 |
| Allopurinol | 11 | $163 | $15 |
| Furosemide | 36 | $150 | $4 |
| Ondansetron Odt | 14 | $133 | $9 |
| Paroxetine | 22 | $88 | $4 |
| Sulfamethoxazole-Trimethoprim | 12 | $86 | $7 |
| Simvastatin | 12 | $77 | $6 |
| Atorvastatin | 13 | $70 | $5 |
| Diazepam | 12 | $66 | $6 |
| Fluticasone Propionate | 11 | $64 | $6 |
| Fluoxetine | 11 | $60 | $5 |
| Amlodipine Besylate | 14 | $57 | $4 |
2014: 42 drugs
| Revlimid | 14 | $136,914 | $9,780 |
| Exemestane | 95 | $36,231 | $381 |
| Fondaparinux | 12 | $30,705 | $2,559 |
| Oxycontin | 11 | $7,945 | $722 |
| Nexium | 21 | $6,416 | $306 |
| Anastrozole | 158 | $4,160 | $26 |
| Cyclosporine | 11 | $2,798 | $254 |
| Duloxetine | 11 | $2,715 | $247 |
| Venlafaxine Hcl Er | 49 | $1,618 | $33 |
| Hydrocodone-Acetaminophen | 49 | $1,454 | $30 |
| Fentanyl | 12 | $1,359 | $113 |
| Oxycodone-Acetaminophen | 25 | $1,286 | $51 |
| Hydroxyurea | 35 | $1,146 | $33 |
| Megestrol Acetate | 16 | $796 | $50 |
| Diphenoxylate-Atropine | 15 | $745 | $50 |
| Nystatin | 26 | $733 | $28 |
| Acyclovir | 48 | $682 | $14 |
| Levothyroxine | 62 | $645 | $10 |
| Ondansetron | 39 | $546 | $14 |
| Potassium Chloride | 18 | $451 | $25 |
| Levofloxacin | 20 | $408 | $20 |
| Pantoprazole | 32 | $379 | $12 |
| Prednisone | 43 | $372 | $9 |
| Gabapentin | 21 | $358 | $17 |
| Dexamethasone | 28 | $290 | $10 |
| Tamoxifen Citrate | 13 | $287 | $22 |
| Prochlorperazine Maleate | 45 | $281 | $6 |
| Hydroxyzine | 20 | $281 | $14 |
| Lorazepam | 51 | $230 | $5 |
| Acetaminophen-Codeine | 15 | $215 | $14 |
| Escitalopram | 23 | $202 | $9 |
| Zolpidem | 27 | $194 | $7 |
| Sulfamethoxazole-Trimethoprim | 28 | $185 | $7 |
| Warfarin | 18 | $182 | $10 |
| Amlodipine Besylate | 18 | $159 | $9 |
| Doxazosin Mesylate | 12 | $142 | $12 |
| Furosemide | 33 | $128 | $4 |
| Fluticasone Propionate | 12 | $119 | $10 |
| Atorvastatin | 13 | $102 | $8 |
| Paroxetine | 13 | $96 | $7 |
| Allopurinol | 15 | $89 | $6 |
| Diazepam | 17 | $87 | $5 |
2013: 49 drugs
| Revlimid | 13 | $154,286 | $11,868 |
| Tarceva | 21 | $114,268 | $5,441 |
| Gleevec | 15 | $94,775 | $6,318 |
| Exemestane | 94 | $25,655 | $273 |
| Anastrozole | 180 | $6,661 | $37 |
| Oxycontin | 15 | $6,015 | $401 |
| Cyclosporine | 14 | $4,243 | $303 |
| Fentanyl | 20 | $2,958 | $148 |
| Nexium | 12 | $2,608 | $217 |
| Hydrocodone-Acetaminophen | 70 | $1,689 | $24 |
| Escitalopram | 26 | $1,434 | $55 |
| Megestrol Acetate | 15 | $1,358 | $91 |
| Venlafaxine Hcl Er | 15 | $1,101 | $73 |
| Hydroxyurea | 29 | $947 | $33 |
| Famciclovir | 13 | $786 | $60 |
| Calcium Acetate | 11 | $732 | $67 |
| Pantoprazole | 26 | $642 | $25 |
| Nystatin | 12 | $628 | $52 |
| Ondansetron | 41 | $594 | $14 |
| Lansoprazole | 13 | $539 | $41 |
| Dexamethasone | 51 | $535 | $10 |
| Diphenoxylate-Atropine | 21 | $491 | $23 |
| Prochlorperazine Maleate | 69 | $463 | $7 |
| Potassium Chloride | 13 | $454 | $35 |
| Gabapentin | 31 | $444 | $14 |
| Levothyroxine | 49 | $442 | $9 |
| Tamoxifen Citrate | 18 | $376 | $21 |
| Amlodipine Besylate | 26 | $353 | $14 |
| Acyclovir | 18 | $344 | $19 |
| Warfarin | 19 | $310 | $16 |
| Prednisone | 41 | $302 | $7 |
| Fluticasone Propionate | 13 | $298 | $23 |
| Tamsulosin | 11 | $291 | $26 |
| Lidocaine-Prilocaine | 11 | $289 | $26 |
| Omeprazole | 18 | $280 | $16 |
| Oxycodone-Acetaminophen | 12 | $241 | $20 |
| Simvastatin | 32 | $223 | $7 |
| Zolpidem | 35 | $213 | $6 |
| Lorazepam | 42 | $200 | $5 |
| Levofloxacin | 18 | $196 | $11 |
| Alendronate | 11 | $136 | $12 |
| Clonidine | 17 | $135 | $8 |
| Furosemide | 26 | $118 | $5 |
| Fluoxetine | 25 | $116 | $5 |
| Sulfamethoxazole-Trimethoprim | 18 | $106 | $6 |
| Lisinopril | 12 | $88 | $7 |
| Alprazolam | 17 | $69 | $4 |
| Doxazosin Mesylate | 11 | $65 | $6 |
| Diazepam | 16 | $58 | $4 |
Money from drug and device companies
$95 in 2025
| 2025 | 2 | 4 | None | $95 |
| 2024 | 2 | 2 | None | $155 |
| 2021 | 1 | 4 | None | $54 |
| 2019 | 1 | 1 | None | $15 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Daiichi Sankyo | Enhertu | $47 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $47 | 2 payments
|
See all 4 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-17 | Enhertu | $17 |
| Daiichi Sankyo | Meals · 2025-10-16 | Enhertu | $18 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-07-15 | None | $30 |
| Daiichi Sankyo | Meals · 2025-01-30 | Enhertu | $29 |
See earlier years (2024, 2021, 2019)
2024: $155
| AstraZeneca Pharmaceuticals LP | Lynparza | $129 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $26 | 1 payment
|
2021: $54
| Acrotech Biopharma | Beleodaq | $54 | 4 payments
|
2019: $15
| Genzyme | Attp Disease | $15 | 1 payment
|
Professional record
- NPI
- 1386603447
- Licence
- CA G83884California G83884: Current · expires 2027-06-30
- Trained
- Yale University School of Medicine, 1993
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G838840
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 150 Harvester Dr Ste 300, Burr Ridge, IL, 60527
- NPI first listed
- 2006-03-18
- NPI last updated
- 2026-08-25
- NPI record certified
- 2026-08-25
This is when the NPI record was last certified, not a medical board exam.